

ideas. answers. action.



# **Episode of Care : The New Math**

### National Bundled Payment Summit Integrated Healthcare Association George Washington University, Washington, DC

#### June 12, 2012

Copyright 2012. This presentation as a whole and all of its individual parts are the exclusive property of The Camden Group.

# Agenda

# Understanding the Risk and Reward Case Study and Discussion





#### The Basics

- Applicants must have submitted a Research Request Packet and Data Use Agreement along with the LOI.
- Applicants received geographic data by HRC
- Data included beneficiary-level claims with masked beneficiary identifiers, Part A and Part B payment amount, MS-DRG, services rendered, dates of services, diagnosis and procedure codes, and institutional provider
- Beneficiary age and sex also included for applicants that choose to propose a risk adjustment methodology
- If data provided by CMS was not used to construct proposed bundled payment, applicant must describe the data used and must be presented in a way that allows for CMS analysis

#### Four Major Components of the Episode Definition

- 1. Define the MS-DRGs you propose to use to define the episode of care
  - a. Provide calendar year 2008 and 2009 volume
- 2. Identify the MS-DRGs you propose to use to exclude beneficiary readmission to an acute care hospital from your episode of care
  - a. Describe rationale why these readmissions should be excluded in the application
- Identify the principal ICD-9 diagnosis codes or MS-DRG codes depending on your model you propose to use to exclude unrelated Part B services during the postdischarge period
  - a. Describe rationale why these services should be excluded in the application
- 4. Define the end of the episode of care
  - a. Minimum 30 days after discharge from the anchor acute care inpatient hospital stay (Model 4 30 days required)
  - CMS encourages applicants to propose a longer period post-hospital discharge because CMS is interested in understanding how care redesign extends to a beneficiary's transition back into the community

#### Sample Analysis – Model 2

#### CMS Sample Data Select MS-DRGs with Highest Episode Payments Model 2

		Model 2 Per Episode Payments								
	Total		30 Days			60 Days		90 Days		
	Number of			Post-			Post-			Post-
RG	Episodes	Part A	Part B	Acute	Part A	Part B	Acute	Part A	Part B	Acute
Major joint replacement or reattachment of lower extremity w/o MCC	54,544	\$10,478	\$4,019	\$7,590	\$10,861	\$4,373	\$8,118	\$11,170	\$4,675	\$8,352
Perc cardiovasc proc w drug-eluting stent w/o MCC	16,401	\$12,775	\$3,122	\$573	\$13,595	\$3,481	\$813	\$14,173	\$3,805	\$1,019
Cardiac defibrillator implant w/o cardiac cath w/o MCC	3,378	\$33,342	\$3,476	\$471	\$34,447	\$3,885	\$645	\$35,137	\$4,253	\$819
Coronary bypass w cardiac cath w/o MCC	3,061	\$27,596	\$9,148	\$3,094	\$28,334	\$9,486	\$3,379	\$28,778	\$9,759	\$3,587
Permanent cardiac pacemaker implant w/o CC/MCC	6,174	\$12,708	\$2,522	\$1,025	\$13,287	\$2,852	\$1,228	\$13,716	\$3,161	\$1,386
Cardiac valve & oth maj cardiothoracic proc w/o card cath w MCC	1,251	\$49,987	\$12,867	\$4,824	\$51,215	\$13,328	\$5,192	\$52,142	\$13,714	\$5,495
Cardiac pacemaker revision except device replacement w CC	294	\$11,474	\$2,996	\$514	\$13,153	\$3,393	\$813	\$13,975	\$3,773	\$958
, , , , , , , , , , , , , , , , , , , ,	,	· · · · ·	* )	<b>i j</b> =	. ,	• • • • =	<b>t</b> = <b>j</b> =	+ - <i>)</i>	,	, i - j

Note 1: Dataset provided by CMS is for the three-year period 2007 to 2009.

#### Sample Analysis – Model 3

#### CMS Sample Data Select MS-DRGs with Highest Episode Payments Model 3

			Model 3 Per Episode Payments							
	Total		30 Days			60 Days			90 Days	
	Number of			Post-	-		Post-			Post-
MS-DRG	Episodes	Part A	Part B	Acute	Part A	Part B	Acute	Part A	Part B	Acute
470: Major joint replacement or reattachment of lower extremity w/o MCC	54,544	\$726	\$2,225	\$7,590	\$1,110	\$2,579	\$8,118	\$1,418	\$2,880	\$8,352
247: Perc cardiovasc proc w drug-eluting stent w/o MCC	16,401	\$1,325	\$1,774	\$573	\$2,145	\$2,133	\$813	\$2,723	\$2,457	\$1,019
227: Cardiac defibrillator implant w/o cardiac cath w/o MCC	3,378	\$1,074	\$1,931	\$471	\$2,178	\$2,341	\$645	\$2,869	\$2,708	\$819
234: Coronary bypass w cardiac cath w/o MCC	3,061	\$1,433	\$4,778	\$3,094	\$2,170	\$5,116	\$3,379	\$2,614	\$5,388	\$3,587
244: Permanent cardiac pacemaker implant w/o CC/MCC	6,174	\$901	\$1,455	\$1,025	\$1,480	\$1,786	\$1,228	\$1,908	\$2,094	\$1,386
219: Cardiac valve & oth maj cardiothoracic proc w/o card cath w MCC	1,251	\$3,057	\$6,885	\$4,824	\$4,285	\$7,345	\$5,192	\$5,212	\$7,732	\$5,495
261: Cardiac pacemaker revision except device replacement w CC	294	\$2,495	\$1,648	\$514	\$4,174	\$2,045	\$813	\$4,996	\$2,425	\$958

Note 1: Dataset provided by CMS is for the three-year period 2007 to 2009.

#### Sample Analysis – Model 4

#### CMS Sample Data Select MS-DRGs with Highest Episode Payments Model 4

		Model 4 Per Episode Payments								
	Total		30 Days			60 Days		90 Days		
	Number of			Post-			Post-			Post-
MS-DRG	Episodes	Part A	Part B	Acute	Part A	Part B	Acute	Part A	Part B	Acute
		<b>•</b> • • • <b>•</b> •	<b></b>		<b>•</b> • • • • • • •	<b>*</b> • • <b>*</b> •		<b>•</b> • • • <b>•</b> •	<b>•</b> • • <b>• •</b>	
470: Major joint replacement or reattachment of lower extremity w/o MCC	54,544	\$10,478	\$4,019		\$10,861	\$4,373		\$11,170	\$4,675	
247: Perc cardiovasc proc w drug-eluting stent w/o MCC	16,401	\$12,775	\$3,122		\$13,595	\$3,481		\$14,173	\$3,805	
227: Cardiac defibrillator implant w/o cardiac cath w/o MCC	3,378	\$33,342	\$3,476		\$34,447	\$3,885		\$35,137	\$4,253	
234: Coronary bypass w cardiac cath w/o MCC	3,061	\$27,596	\$9,148		\$28,334	\$9,486		\$28,778	\$9,759	
244: Permanent cardiac pacemaker implant w/o CC/MCC	6,174	\$12,708	\$2,522		\$13,287	\$2,852		\$13,716	\$3,161	
219: Cardiac valve & oth maj cardiothoracic proc w/o card cath w MCC	1,251	\$49,987	\$12,867		\$51,215	\$13,328		\$52,142	\$13,714	
261: Cardiac pacemaker revision except device replacement w CC	294	\$11,474	\$2,996		\$13,153	\$3,393		\$13,975	\$3,773	

Note 1: Dataset provided by CMS is for the three-year period 2007 to 2009.

### Financial Projection – Year 1

#### CMMI Bundled Payments - Model 4 Cardiac Service Line (ACE Demonstration MS-DRGs) Financial Projection - Year 1 CY 2010

	Share Growth	With Market Share Growth
CMMI Payment Discount (Must be Greater than 3%)	3.25%	3.25%
Target Average Length-of-Stay (Premier 90th %tile)	3.4	3.4
Supply Cost Reduction (Implantable Devices)	20%	20%
Percent Increase in Volume (Market Share Growth)	0%	5%
Incremental Cases	0	25
Current Medicare FFS Cases	500	500
Current Contribution Margin	\$5,137,284	\$5,137,284
Current Contribution Margin per Case	\$10,275	\$10,275
Financial Impact		
Incremental Program Costs of CMMI Program	(\$350,000)	(\$350,000)
CMMI Payment Discount	(452,236)	(452,236)
Average Length-of-Stay Reduction	576,077	576,077
Supply Cost Reduction	979,993	979,993
Market Share Growth	0	312,056
Total Financial Impact	\$753,834	\$1,065,890
New Total Number of Medicare FFS Cases	500	525
New Contribution Margin before Gainsharing	\$5,891,118	\$6,203,174
New Contribution Margin per Case	\$11,782	\$11,816
Dollars Available for Gainsharing	\$753,834	\$809,026
Gainsharing Payments (50% of Dollars Available NTE 50% of Part B)	(\$376,917)	(\$404,513)
New Contribution Margin after Gainsharing	\$5,514,201	\$5,798,661
Percent Change in Contribution Margin	7.3%	12.9%

Note: This analysis does not calculate additional opportunities to reduce costs such as reducing readmissions, reducing ancillary and consult utilization, and the spillover effects of these initiatives to other areas of the Hospital.

### Discount and Market Share Growth Scenarios – Year 1

CMMI Bundled Payments - Model 4

Cardiac Service Line (ACE Demonstration MS-DRGs)

CMMI Payment Discount and Market Share Growth Scenarios Assuming Cost Reduction Initiatives are Achieved

New Contribution Margin - Year 1

CY 2010

	Financial Risk and Competitive Pricing CMMI Payment Discount in Percent and Dollars										
				3.25%	3.50%	3.75%	4.00%	4.25%	4.50%	4.75%	5.00%
				(\$452,236)	(\$487,023)	(\$521,811)	(\$556,598)	(\$591,386)	(\$626,173)	(\$660,960)	(\$695,748)
	ases	0.0%	0	\$5,514,201 *	\$5,496,807	\$5,479,414	\$5,462,020	\$5,444,626	\$5,427,233	\$5,409,839	\$5,392,445
	Percent Increase in Volume and Incremental Cases	5.0%	25	\$5,798,661 *	\$5,781,267	\$5,763,874	\$5,746,480	\$5,729,086	\$5,711,693	\$5,694,299	\$5,676,905
are Growth	ie and Incr	7.5%	38	\$6,069,323	\$6,051,929	\$6,034,536	\$6,017,142	\$5,999,748	\$5,982,355	\$5,964,961	\$5,947,567
Market Share	se in Volum	10.0%	50	\$6,404,201	\$6,386,808	\$6,369,414	\$6,352,020	\$6,334,627	\$6,317,233	\$6,299,839	\$6,282,446
	ent Increas	12.5%	63	\$6,803,296	\$6,785,902	\$6,768,508	\$6,751,114	\$6,733,721	\$6,716,327	\$6,698,933	\$6,681,540
	Perc	15.0%	75	\$7,266,606	\$7,249,212	\$7,231,818	\$7,214,425	\$7,197,031	\$7,179,637	\$7,162,244	\$7,144,850

**Current Contribution Margin** 

\$5,137,284

\* Denotes the assumptions used for Financial Projection table

#### CMMI Bundled Payments - Model 4 Cardiac Service Line (ACE Demonstration MS-DRGs) Risk Analysis if Cost Reduction Initiatives are Not Achieved - Year 1 CY 2010

	CMMI Program NOT Awarded	CMMI Program Awarded
Current Contribution Margin	\$5,137,284	\$5,137,284
Financial Impact		
Incremental Program Costs	\$0	(\$350,000)
CMMI Payment Discount (3.25%)	0	(452,236)
Loss of Market Share (5% decrease in cases)	(256,864)	0
Readmissions Penalty (1% starting FFY 2013)	(120,000)	0
Value-Based Purchasing Risk (1% starting FFY 2013)	(120,000)	0
Hospital-Acquired Conditions Penalty (1% starting FFY 2015)	(120,000)	0
Total Financial Impact	(\$616,864)	(\$802,236)
New Contribution Margin Percent Change in Contribution Margin	\$4,520,420 -12.0%	\$4,335,048 -15.6%


Note: The Health Reform risks calculated here are based on the service line Medicare payments only and not the impact hospital-wide.

## Gainsharing Payments – Year 1 and Maximum

#### CMMI Bundled Payments - Model 4 Cardiac Service Line (ACE Demonstration MS-DRGs) Gainsharing Payments - Year 1 CY 2010

	Without Market Share Growth	With Market Share Growth
CMMI Payment Discount (Must be Greater than 3%)	3.25%	3.25%
Target Average Length-of-Stay (Premier 90th %tile)	3.4	3.4
Supply Cost Reduction (Implantable Devices)	20%	20%
Percent Increase in Volume (Market Share Growth)	0%	5%
Incremental Cases	0	25
Projected Medicare FFS Cases	500	525
Projected Gainsharing Payments from Financial Projection	\$376,917	\$404,513
Maximum Gainsharing Payments (50% of Part B)	\$734,035	\$770,737
Projected Gainsharing Payment per Case	\$754	\$771
Maximum Gainsharing Payment per Case	\$1,468	\$1,468
Projected Gainsharing Payment as % of Part B	26%	26%

### Gainsharing by Physician Example



THE CAMDEN GROUP


# Agenda

Understanding the Risk and Reward Case Study and Discussion






SUMMARY COST MODEL (figures rounded)	Average Allowed Cost/Patient Having MS-DRG 22					
Inpatient Cost Categories	Avg. Cost	Post-acute Care Cost Categories (30 Days)	Avg. Cost			
Facility Inpatient Surgical	40,673	Inpatient Readmissions	890			
Prof. Inpatient Surgery - Primary surgeon	1,075	Skilled Nursing Facility	599			
All Other	324	Other Outpatient Prof.	227			
Prof. Inpatient Visits - General	206	Other Outpatient Facility (lab, radiology, etc.)	215			
Prof. Inpatient Anesthesia	162	Acute Inpatient Rehab	200			
Other Ambulance	152	Home Care	175			
Prof. Radiology Inpatient	60	Part B Drugs	32			
Prof. Consults	56	OP Rehab	6			
Other DME and Supplies	11	Long-term Acute Care (LTAC)	-			
Prof. Pathology/Lab Inpatient	1	Other Including DME				
Prof. Inpatient Surgery - Assistant Surgeon						
Total Inpatient Claims Per Patient	42,722	Total post-acute care claims per patient	2,982			
Total bundle claim costs per patient (IP and 30 days after dc) * Average cost per patient reflects some patients not receiving some services; total costs for each service are average across the hip/knee surgery population	\$45,704					




#### THE CAMDEN GROUP


#### Post Acute Avg. Cost



SUMMARY COST MODEL (figures rounded)	Average Allowed Cost/Patient Having MS-DRG 24					
Inpatient Cost Categories	Avg. Cost	Post-acute Care Cost Categories (30 Days)	Avg. Cost			
Facility Inpatient Surgical	14,782	Inpatient Readmissions	1,085			
Prof. Inpatient Surgery - Primary Surgeon	518	Skilled Nursing Facility	1,030			
Prof. Inpatient Visits - General	271	Other Outpatient Facility (lab, radiology, etc.)	288			
Other Ambulance	209	Other Outpatient Prof.	208			
All Other	184	Home Care	208			
Prof. Consults	91	Acute Inpatient Rehab	113			
Prof. Inpatient Anesthesia	64	Part B Drugs	31			
Prof. Radiology Inpatient	62	OP Rehab	8			
Other DME and Supplies	5	Long-term Acute Care (LTAC)	0			
Prof. Pathology/Lab Inpatient	2	Other Including DME	0			
Prof. Inpatient Surgery - Assistant Surgeon			0			
Total Inpatient Claims Per Patient	16,188	Total post-acute care claims per patient	2,971			
Total bundle claim costs per patient (IP and 30 days after dc) * Average cost per patient reflects some patients not receiving some services; total costs for each service are average across the hip/knee surgery population	\$19,159					



#### Post Acute Avg. Cost




# Episodic Cost: DRG 470 Major Joint (Hip or Knee)

SUMMARY COST MODEL (figures rounded)	Average Allowed Cost/Patient Having Hip/Knee Surgery Admissions *	Post -acute Care Cost Categories (30 days)	Average Allowed Cost/Patient Having Hip/Knee Surgery Admissions *
Inpatient Cost Categories	Avg. Cost	Post-acute Care Cost Categories	Avg. Cost
Facility Inpatient Surgical	13,800	Skilled Nursing Facility	4,500
Prof. Inpatient Surgery - Primary surgeon	1,560	Acute Inpatient Rehab	1,800
Prof. Inpatient Anesthesia	780	Home care	1,200
Prof. Inpatient Visits - General	360	Inpatient readmissions	900
Prof. Inpatient Surgery - Assistant surgeon	240	Other outpatient Prof.	240
Other Ambulance	240	OP rehab	210
		Other outpatient facility (lab,	
Prof. Radiology Inpatient	120	radiology, etc)	90
Other DME and Supplies	120	Long-term Acute Care (LTAC)	36
Prof. Consults	72	Part B drugs	24
Prof. Pathology/Lab - Office - Independent Lab		Other including DME	12
Prof. Pathology/Lab Inpatient	18		
		Total post-acute care claims per	
Total inpatient claims per patient	\$17,346	patient	\$9,012
Total bundle claim costs per patient (IP and 30 days after dc) \$26,358 * Average cost per patient reflects some patients			

\* Average cost per patient reflects some patients not receiving some services; total costs for each service are average across the hip/knee surgery population


# DRG 470 Major Joint Spend for Inpatient

### Inpatient Average Cost



### DRG 470 Major Joint Post-acute Spend

#### Post-acute Average Costs



Robert Minkin, MBA The Camden Group Senior Vice President rminkin@TheCamdenGroup.com

Deirdre Baggot, Ph.D.(c), MBA,RN The Camden Group Vice President DBaggot@TheCamdenGroup.com





THE CAMDEN GROUP



THE

6/12/2012 | 23